newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month

BIAFBIAFW
  • bioAffinity Technologies, Inc. will share CyPath® Lung benefits with the North Carolina patient advocacy & healthcare community at the November 5, 2026 "Battle of the Blues" event during National Lung Cancer Awareness Month.
  • The event will present results from major trials intended to change physician practice & provide actionable thoracic oncology results to improve lung cancer patient care.
  • Maria Zannes, President & CEO of bioAffinity Technologies, emphasized that early lung cancer detection can lead to curative therapy & highlighted recent advancements in diagnosis & treatment.
  • CyPath® Lung is a noninvasive, patent-protected assay that analyzes lung microenvironments using advanced flow cytometry, AI-driven analysis, & a proprietary fluorescent porphyrin (TCPP) to identify malignancy-indicating cell populations in patient sputum.
  • The test provides a binary result of "Likely" or "Unlikely" for malignancy to help physicians assess lung cancer risk in patients with pulmonary nodules & guide follow-up decisions.
  • Clinical case studies indicate CyPath® Lung can detect lung cancer as early as curative Stage 1A, though decisions should be based on the patient's overall clinical evaluation.
  • A published clinical trial of high-risk patients with small indeterminate lung nodules (<20mm) demonstrated 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value (NPV) for CyPath® Lung.
  • CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, & is overseen under CLIA regulations administered by CMS.
  • The test is not intended for use as a sole diagnostic tool & should be considered alongside other clinical findings.
  • The press release includes forward-looking statements regarding potential future results & patient outcomes, warning of risks such as the possibility that cited results may not be replicated in broader populations.